SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
Status:
Completed
Trial end date:
2022-03-25
Target enrollment:
Participant gender:
Summary
This is the first phase 3 randomized, double-blind, placebo/active-controlled clinical study
to evaluate the efficacy and long-term safety of SAL067 in treatment-naive T2DM patients
uncontrolled with diet and exercise intervention, comprising 24 weeks of double-blind
treatment period followed by an open-label treatment period, making up a total of 52 weeks.